What is the current valuation of the US irritable bowel-syndrome-treatment market?

The market valuation was $440.48 Million in 2024. Read More

What is the projected market size for the US irritable bowel-syndrome-treatment market by 2035?

The market is expected to reach $1,039.69 Million by 2035. Read More

What is the expected CAGR for the US irritable bowel-syndrome-treatment market during the forecast period 2025 - 2035?

The expected CAGR is 8.12% during the forecast period. Read More

Which companies are the key players in the US irritable bowel-syndrome-treatment market?

Key players include AbbVie Inc, Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, AstraZeneca plc, Pfizer Inc, Bristol-Myers Squibb Company, and Johnson & Johnson. Read More

What are the main segments of the US irritable bowel-syndrome-treatment market?

The main segments include IBS-D, IBS-C, and IBS-M, with respective valuations of $150.12 Million, $180.24 Million, and $110.12 Million. Read More

How do the drug types in the US irritable bowel-syndrome-treatment market compare in terms of valuation?

Drug types include Lubiprostone at $70.0 Million, Linaclotide at $90.0 Million, Rifaximin at $80.0 Million, Eluxadoline at $60.0 Million, and Alosetron at $40.48 Million. Read More

What is the valuation of the end-user segments in the US irritable bowel-syndrome-treatment market?

End-user segments include Hospitals at $176.19 Million, Clinics at $132.14 Million, Research Laboratories at $88.09 Million, and Others at $44.06 Million. Read More

What is the growth outlook for the IBS-C segment in the US irritable bowel-syndrome-treatment market?

The IBS-C segment is projected to grow from $180.24 Million in 2024 to a higher valuation by 2035. Read More

How does the performance of the IBS-D segment compare to other segments?

The IBS-D segment had a valuation of $150.12 Million in 2024, indicating a competitive position among other segments. Read More

What factors may influence the growth of the US irritable bowel-syndrome-treatment market?

Factors influencing growth may include advancements in treatment options, increasing awareness, and the rising prevalence of IBS. Read More

What is the expected market size for the US Irritable Bowel Syndrome Treatment Market in 2024?

The US Irritable Bowel Syndrome Treatment Market is expected to be valued at 441.0 million USD in 2024. Read More

How much is the US Irritable Bowel Syndrome Treatment Market projected to grow by 2035?

By 2035, the market is projected to reach a valuation of 1039.9 million USD. Read More

Which segment in the US Irritable Bowel Syndrome Treatment Market shows significant revenue and growth potential?

The IBS-D segment is expected to grow from 132.0 million USD in 2024 to 331.0 million USD by 2035. Read More

What is the projected market size for the IBS-C segment in 2035?

The IBS-C segment is projected to reach a valuation of 392.0 million USD by 2035. Read More

What is the market valuation for the IBS-M segment in 2024?

The IBS-M segment is valued at 149.0 million USD in the year 2024. Read More

How is the competitive landscape in the US Irritable Bowel Syndrome Treatment Market characterized?

The market features strong competition from pharmaceutical companies such as Takeda Pharmaceuticals and AbbVie, among others. Read More

What are some challenges that the US Irritable Bowel Syndrome Treatment Market may face?

Key challenges in the market include regulatory hurdles and the need for more effective treatment options. Read More

What growth opportunities exist within the US Irritable Bowel Syndrome Treatment Market?

The increasing prevalence of Irritable Bowel Syndrome and ongoing research for new therapies present significant growth opportunities. Read More

US Irritable Bowel Syndrome Treatment Market

US Irritable Bowel Syndrome Treatment Market Research Report: Size, Share, Trend Analysis By Types (IBS-D, IBS-C, IBS-M), By Drug Type (Lubiprostone, Linaclotide, Rifaximin, Eluxadoline, Alosetron), and By End-user (Hospitals, Clinics, Research Laboratories, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

8.12%

2024 Market Size

$ 440.48 Million

2035 Market Size

$ 1,039.69 Million

Healthcare ● Updated August 2026 Report ID: MRFR/HC/16513-CR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Million)
  1. 4.1.1 IBS-D
  2. 4.1.2 IBS-C
  3. 4.1.3 IBS-M
2. 4.2 Healthcare, BY Drug Type (USD Million)
  1. 4.2.1 Lubiprostone
  2. 4.2.2 Linaclotide
  3. 4.2.3 Rifaximin
  4. 4.2.4 Eluxadoline
  5. 4.2.5 Alosetron
3. 4.3 Healthcare, BY End-User (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Research Laboratories
  4. 4.3.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Takeda Pharmaceutical Company Limited (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GlaxoSmithKline plc (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca plc (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer Inc (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Johnson & Johnson (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DRUG TYPE
4. 6.4 US MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF HEALTHCARE
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF HEALTHCARE
8. 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
9. 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
11. 6.11 HEALTHCARE, BY TYPE, 2024 (% SHARE)
12. 6.12 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY END-USER, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US US Irritable Bowel Syndrome Treatment Market Segmentation

US Irritable Bowel Syndrome Treatment Market By Type (USD Million, 2025-2035)

IBS-D
IBS-C
IBS-M

US Irritable Bowel Syndrome Treatment Market By Drug Type (USD Million, 2025-2035)

Lubiprostone
Linaclotide
Rifaximin
Eluxadoline
Alosetron

US Irritable Bowel Syndrome Treatment Market By End-User (USD Million, 2025-2035)

Hospitals
Clinics
Research Laboratories
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”